RYTM RHYTHM PHARMACEUTICALS, INC.

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business: Development and commercialization of MC4R agonist therapies to treat rare neuroendocrine diseases causing severe obesity and hyperphagia
• • New product focus: Anticipated 2026 US launch of IMCIVREE for acquired hypothalamic obesity, plus Phase 3 trial initiation for oral MC4R agonist bivamelagon

Risk Factors

• • Regulatory risk from FDA, EC, MHRA approvals for setmelanotide expansion delays or denials impacting U.S., Canada, EU, UK launch
• • Geopolitical risk due to European operations and recent acquisition of Netherlands-based Xinvento B.V., with CHI program still in discovery phase

Management Discussion & Analysis

• • Revenue $422.5M to date from IMCIVREE product sales; commercial launch in US Q1 2021, France March 2022, ongoing growth expected
• • Net loss $196.5M in 2025 vs $260.6M in 2024; operating expenses increased with R&D down to $167.3M from $238M, SG&A up to $194.9M from $144.3M

Risk Factors

• • New risk from July 2025 $188.7M follow-on public offering; impact on capital structure and dilution risk increased
• • RIFA royalty burden update: tiered royalties 11.5%-2.5% on net revenues up to $300M+, $34.9M paid through Sept 2025, limits cash flow flexibility

What are the latest RYTM SEC filings in 2026?

RHYTHM PHARMACEUTICALS, INC. (RYTM) has filed a 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 4, 2025, an 8-K current report on April 3, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did RYTM file its most recent 10-K annual report?

RHYTHM PHARMACEUTICALS, INC. (RYTM) filed its most recent 10-K annual report on February 26, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view RYTM 10-Q quarterly reports?

RHYTHM PHARMACEUTICALS, INC. (RYTM)'s most recent 10-Q quarterly report was filed on November 4, 2025. SignalX displays every RYTM 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has RYTM filed recently?

RHYTHM PHARMACEUTICALS, INC. (RYTM)'s most recent 8-K was filed on April 3, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find RYTM insider trading activity (Form 4)?

SignalX aggregates every RYTM Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does RYTM file with the SEC?

RHYTHM PHARMACEUTICALS, INC. (RYTM) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new RYTM filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for RHYTHM PHARMACEUTICALS, INC. (RYTM).

What is RYTM's SEC CIK number?

RHYTHM PHARMACEUTICALS, INC. (RYTM)'s SEC CIK (Central Index Key) number is 1649904. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1649904 to look up all RYTM filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find RYTM return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from RHYTHM PHARMACEUTICALS, INC. (RYTM) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.